Oral menin inhibitor plus AML medicines for new or relapsed AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an all-pill (oral) combination treatment—menin inhibitor SNDX-5613 plus decitabine/cedazuridine (ASTX727) and venetoclax—for acute myeloid leukemia (AML). It’s designed for people who are newly diagnosed and can’t get the strongest chemotherapy, or for certain other AML groups who may still benefit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re at least 12 years old and weigh at least 40 kg (about 88 lb).
- You can do most daily activities (performance status score of 0–2).
- You have AML that fits the trial group: newly diagnosed but not eligible for high-intensity induction chemotherapy, or a specific relapsed/refractory/myeloid-type group (as defined by the trial).
- Your white blood cell count is under 25,000 at enrollment (you may get short-term treatment to lower it first).
- Your heart and organ function meet safety cutoffs (including ejection fraction over 40% and adequate liver and kidney tests).
- You can take oral medicines reliably, avoid certain other cancer drugs during the study, and agree to birth control rules to prevent pregnancy during and for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial studies a 3-drug combination to treat certain types of acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) in adults. It may help by targeting cancer cells using different medicines, especially for people who may not be able to get intensive chemotherapy.
This Phase 2 trial tests a combination of venetoclax, cladribine, low-dose cytarabine, and azacitidine in people with untreated acute myeloid leukemia (AML). It may help shrink the leukemia and improve blood counts by trying a stronger, multi-drug approach.
This early-phase study tests a menin inhibitor drug (SNDX-5613) combined with standard induction chemotherapy (daunorubicin plus cytarabine) in newly diagnosed AML with specific gene changes (NPM1 or FLT3 status, or MLL/KMT2A or NUP98). It may help patients whose AML has these genetic features respond better to intensive treatment.
This trial tests a combination of three oral medications (chidamide, venetoclax, and azacitidine) for people newly diagnosed with acute myeloid leukemia (AML) who cannot receive strong chemotherapy. The goal is to see if this gentler treatment can work well with fewer side effects.
This early-phase study tests whether venetoclax combined with intensive chemotherapy can treat AML (acute leukemia) and certain advanced MDS. It’s for people who are newly diagnosed (or certain high-risk blood cancers) and can safely tolerate strong treatment.
This trial tests two targeted drugs, venetoclax and revumenib, for people with acute myeloid leukemia (AML) that has a specific change in the NPM1, KMT2A, or NUP98 genes and has minimal residual disease (MRD) after treatment. The goal is to see if this combination can clear remaining leukemia cells and improve outcomes.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.